Tiny InnerDyne takes on giant rivals in US trocar market
This article was originally published in Clinica
Executive Summary
InnerDyne is poised to take a 10% share of the highly competitive US trocar market, which includes two of the top five medical device companies, Johnson & Johnson and Tyco. President and CEO William Mavity told the US bancorp Piper Jaffray Health Care conference in New York earlier this month why the small company is such an irritant to its larger rivals.